What human research says about hydrogen–oxygen inhalation
Multiple human studies have evaluated electrolytically generated gas containing approximately two parts hydrogen and one part oxygen. Researchers have reported promising results in several defined clinical settings, but the evidence remains emerging and tied to specific devices, doses, protocols, and patient populations.
Real human studies exist—but their scope matters.
The studies below directly involve hydrogen–oxygen mixed gas rather than only low-concentration molecular hydrogen diluted in air. They include randomized trials, multicenter studies, and smaller exploratory investigations.
The findings cannot automatically be generalized to different generators, gas purity, flow rates, delivery systems, exposure times, diseases, or users. They also do not demonstrate that Efena equipment has been clinically validated or authorized for these indications.
Reported results and important limitations
Symptoms during acute COPD exacerbation
A ten-center controlled trial compared a hydrogen–oxygen mixture with oxygen therapy in patients experiencing an acute exacerbation of chronic obstructive pulmonary disease. At day seven, the hydrogen–oxygen group had a larger improvement in the Breathlessness, Cough, and Sputum Scale and in cough-assessment scores.
What did not differ: The groups did not show significant differences in pulmonary function, arterial blood gases, or several other endpoints. The study addressed short-term adjunctive treatment in monitored patients—not routine home use or disease prevention.
Modest short-term blood-pressure changes
Adults aged 50–70 were assigned to placebo air or a 66% hydrogen and 33% oxygen mixture for four hours daily over two weeks. Fifty-six completed the study. Investigators reported reductions of approximately 4.8–5.0 mmHg in measured arm systolic blood pressure and a 2.7 mmHg reduction in nighttime ambulatory diastolic pressure within the mixed-gas group.
Limitations: The trial was small and short, lacked delayed follow-up, and many 24-hour ambulatory measures did not change significantly. It does not support replacing prescribed hypertension care.
Changes in liver fat and biological markers
A 13-week trial evaluated hydrogen–oxygen inhalation in people with non-alcoholic fatty liver disease. Forty-three participants completed the study. The authors reported improvement in liver-fat measurements and reductions in selected oxidative-stress and inflammatory biomarkers.
Limitations: The completion rate was about 69–70% in the study groups, the final sample was small, and the findings require confirmation in larger independent trials. The study does not establish a generally accepted treatment.
Adjunctive use alongside standard care
In a seven-hospital randomized study, 32 hospitalized patients received hydrogen–oxygen mixed gas and 32 received oxygen, in addition to standard care. Investigators reported a shorter average viral-shedding period, changes in interleukin-6 and lymphocyte measurements, and more resolution of pulmonary lesions in the mixed-gas group.
Limitations: This was a small, short-duration study of one SARS-CoV-2 variant in hospitalized patients. It does not support self-treatment, replace vaccination or established care, or demonstrate effectiveness for other respiratory infections.
Sleep-time and sleep-efficiency measurements
A single-blind randomized trial compared air with a 66.7% hydrogen and 33.3% oxygen mixture delivered for seven days. The authors reported improvements in total sleep time and sleep efficiency at several measurement points, along with reductions in wake time on selected days.
Limitations: The trial was short, the groups were unequal in size, and the authors stated that this application remains at the clinical-trial stage. Longer, independently replicated studies are needed.
Reduced inspiratory effort
A clinical study reported that breathing a hydrogen–oxygen mixture reduced inspiratory effort in patients with tracheal stenosis. The lower density of the mixture may contribute mechanically to airflow through a narrowed airway, separately from any proposed biological effect of hydrogen.
Limitation: This finding concerns a specific respiratory obstruction and controlled delivery conditions. It cannot be generalized as evidence of broad health improvement.
Used alongside home-based exercise
A randomized trial studied hydrogen–oxygen inhalation as an addition to home exercise in older adults with knee osteoarthritis. This expands the research beyond respiratory and metabolic applications.
Limitation: The intervention was adjunctive and the study does not establish hydrogen–oxygen inhalation as a replacement for evidence-based osteoarthritis care.
Convalescent COVID-19 protocol
A registered randomized study specified an electrolytic generator producing gas at 3 L/min with 66.7% hydrogen and 33.3% oxygen, compared with oxygen, for eight hours per day over twelve weeks. A registered protocol demonstrates active scientific investigation; it is not itself proof of benefit.
The responsible conclusion
Yes—published human research has directly evaluated the approximately 2:1 hydrogen–oxygen mixture commonly associated with the term “HHO.” Several controlled trials reported promising signals, particularly for symptom relief or selected physiological measurements.
The evidence is still condition-specific and developing. It does not validate every generator, prove broad “health improvement,” authorize consumer self-treatment, or establish that Efena equipment produces the same clinical outcomes.
Medical use requires more than a promising paper.
Gas composition, contaminants, flow rate, dilution with room air, cannula or mask design, ventilation, ignition control, alarms, cleaning, electrical safety, labeling, training, and clinical monitoring can all affect risk. A system intended for medical use must follow the regulatory pathway of the destination country and the intended clinical claim.
In the United States, FDA establishment registration or device listing does not by itself mean that a product is cleared, approved, or authorized for medical marketing.
- Hydrogen–oxygen therapy in acute COPD exacerbation
- Low-dose hydrogen–oxygen inhalation in hypertension
- Hydrogen–oxygen inhalation for fatty liver disease
- Hydrogen–oxygen therapy in Omicron infection
- Hydrogen–oxygen inhalation and sleep disorders
- Hydrogen–oxygen mixture and inspiratory effort
- Hydrogen–oxygen inhalation with home exercise for knee osteoarthritis
- Registered 66.7% hydrogen/33.3% oxygen clinical protocol
- FDA explanation of registration, clearance, approval, and authorization
Discuss a qualified institutional project.
Efena can evaluate technical and international supply requirements with research institutions, healthcare organizations, and experienced distributors, subject to the applicable regulatory pathway.
Contact Efena